PresbyopiaNCT07384182
Clinical Outcomes of Femtosecond Laser Presbyopia Treatment in Monofocal IOLs
A study testing Perfector in people with Presbyopia, run by Perfect Lens, LLC at 1 site in Czechia.
Trial summary
This study aimed to assess the safety and efficacy of treating presbyopia in eyes implanted with a mono focal IOL using a low-energy femtosecond laser. Read more about this study
- Who is it for?
- Any ageHealthy volunteers can take part
- Conditions the study is for
- Presbyopia
- What is being tested?
- Perfector
- Type of treatment
- Medical device
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 19 participants
- Where
- 1 siteCzechia
- Study dates
- 15 Oct 2023to 12 Nov 2024
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages Any age
- All sexes
- Healthy volunteers accepted
- Child, Adult, Older adult
Who may be able to join
- Ability to understand study requirements, follow study instructions and to return for required study follow-up visits as confirmed by provision of written informed consent;
- Subject has undergone cataract surgery and has had a monofocal lens implanted in both eyes;
- Subject has no significant residual visual issues which the Investigator believes would make the patient ill suited for the Treatment.; and
- Both eyes have CDVA vision of 20/25 or better at 4m.
Who cannot join
- Subjects not able to complete the informed consent form;
- Clinically significant corneal abnormalities including corneal dystrophy (e.g., epithelial, stromal, or endothelial dystrophy), inflammation, keratitis, keratoconjunctivitis, keratouveitis, keratopathy, keratectasia or edema per the Investigator's expert medical opinion;
- Previous corneal surgery;
- Previous refractive surgery or proposed refractive surgery procedures throughout the entire duration of the subjects' participation in the clinical study (including, but not limited to LASIK, astigmatic keratotomy and limbal relaxing incisions);
- History of or current retinal conditions or predisposition to retinal conditions including retinal detachment, diabetic retinopathy, age related macular degeneration which are assessed to by investigator to confound outcomes;
- Amblyopia;
Show all 13Show fewer
- History of or current anterior or posterior segment inflammation of any etiology, or any disease-producing an inflammatory reaction in the eye (e.g., iritis or uveitis);
- Optic nerve atrophy;
- Iris neovascularization;
- Subjects with diagnosed degenerative eye disorders (e.g., macular degeneration or other retinal disorders);
- Uncontrolled glaucoma;
- Any subject currently participating in another investigational drug or device studies; and
- Any subject disqualified by the Principal Investigator or Medical Monitor for any ocular issue.
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Assessment of Clinical and Refractive Outcomes of the Use of a Femtosecond to Treat the Symptoms of Presbyopia in a Patient With Implanted Mono Focal IOLs
This study aimed to assess the safety and efficacy of treating presbyopia in eyes implanted with a mono focal IOL using a low-energy femtosecond laser.
Read the detailed description
An investigative device built by Perfect Lens was used to adjust an implanted IOL in 38 eyes.
The device uses a femtosecond laser, a scanner, and an OCT. Each patient was presbyopic pre-treatment. The primary endpoint for the treatment was to create near vision in the treated eye without sacrificing the existing far vision. The first patient was treated in October 2023 and the last patient was treated in July 2024. The last patient visit was in November 2024.
The patients were examined at 7 days, 30 days and 90 days after treatment.
- Conditions
- Presbyopia
- Being tested
- Perfector
- Medical subject headings
- Presbyopia
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
PerfectorDevice
The Perfector is used in the procedure. The Device is attached to the patient by the use of a patient attachment. The patient attachment attaches to the sclera of the eye using vacuum pressure.
| Study group | Role | What they receive |
|---|---|---|
| Application of Perfector laser treatment | Experimental | Active treatment arm Receives: Device: Perfector |
What is being measured
The primary outcome is the main question the study is designed to answer.
Distance corrected near visual acuity (DCNVA) at 40 cm
Visual acuity (VA) was tested monocularly and binocularly (both eyes together) using the manifest refraction and the hand-held, 100% contrast, Early Treatment Diabetic Retinopathy Study (ETDRS) chart set at 40 centimeters (cm) on the nearpoint rod. VA was measured in logarithm minimum angle of resolution (logMAR) increments, with 0.1 logMAR corresponding to 5 letters, or 1 line, on the ETDRS chart. A lower logMAR value denotes better visual acuity.
The hypothesis tested for is to demonstrate superiority of the near vision of treated IOL to the IOL pre-treatment.
Measured: 1 month after treatment
Distance corrected intermediate visual acuity (DCIVA) at 66 cm
Visual acuity (VA) was tested monocularly and binocularly (both eyes together) using the manifest refraction and the hand-held, 100% contrast, Early Treatment Diabetic Retinopathy Study (ETDRS) chart set at 66 centimeters (cm) on the nearpoint rod. VA was measured in logarithm minimum angle of resolution (logMAR) increments, with 0.1 logMAR corresponding to 5 letters, or 1 line, on the ETDRS chart. A lower logMAR value denotes better visual acuity.
The hypothesis tested for is to demonstrate non-inferiority of the treated IOL to the pre-treated IOL (using a non-inferiority margin of 0.10 logMAR).
Measured: 1 month after treatment
Corrected distance visual acuity (CDVA) at 4 m
Visual acuity (VA) was tested monocularly and binocularly (both eyes together) using the manifest refraction adjusted for infinity and stand Early Treatment Diabetic Retinopathy Study (ETDRS) chart set at 4 meters (m) on the nearpoint rod. VA was measured in logarithm minimum angle of resolution (logMAR) increments, with 0.1 logMAR corresponding to 5 letters, or 1 line, on the ETDRS chart. A lower logMAR value denotes better visual acuity.
The hypothesis tested for the co-primary effectiveness endpoint is to demonstrate non-inferiority of the treated IOL to the pre-treatment IOL (using a non-inferiority margin of 0.10 logMAR).
Measured: 1 month after treatment
Secondary outcomes (15)
Uncorrected distance visual acuity (UDVA)
Visual acuity (VA) was tested monocularly and binocularly (both eyes together) adjusted for infinity and stand Early Treatment Diabetic Retinopathy Study (ETDRS) chart set at 4 meters (m) on the nearpoint rod. Without the manifest refraction. VA was measured in logarithm minimum angle of resolution (logMAR) increments, with 0.1 logMAR corresponding to 5 letters, or 1 line, on the ETDRS chart. A lower logMAR value denotes better visual acuity.
Measured: 1 week, 1month and 3 months after treatment
Uncorrected intermediate visual acuity at 66 cm (UIVA)
Visual acuity (VA) was tested monocularly and binocularly (both eyes together) using 100% contrast, Early Treatment Diabetic Retinopathy Study (ETDRS) chart set at 66 centimeters (cm) on the nearpoint rod. Without manifest refraction. VA was measured in logarithm minimum angle of resolution (logMAR) increments, with 0.1 logMAR corresponding to 5 letters, or 1 line, on the ETDRS chart. A lower logMAR value denotes better visual acuity.
Measured: 1 week, 1month and 3 months after treatment
Uncorrected near visual acuity at 40 cm (UNVA)
Visual acuity (VA) was tested monocularly and binocularly (both eyes together) using 100% contrast, Early Treatment Diabetic Retinopathy Study (ETDRS) chart set at 40 centimeters (cm) on the nearpoint rod. Without manifest refraction. VA was measured in logarithm minimum angle of resolution (logMAR) increments, with 0.1 logMAR corresponding to 5 letters, or 1 line, on the ETDRS chart. A lower logMAR value denotes better visual acuity.
Measured: 1 week, 1month and 3 months after treatment
Corrected near visual acuity at 40 cm (CNVA)
Visual acuity (VA) was tested monocularly and binocularly (both eyes together) using manifest refraction100% contrast, Early Treatment Diabetic Retinopathy Study (ETDRS) chart set at 40 centimeters (cm) on the nearpoint rod. VA was measured in logarithm minimum angle of resolution (logMAR) increments, with 0.1 logMAR corresponding to 5 letters, or 1 line, on the ETDRS chart. A lower logMAR value denotes better visual acuity.
Measured: 1 week, 1month and 3 months after treatment
Defocus curve
To assess the defocus curve the same optotype as for the distance visual acuity will be used. The test will be performed with the best distance corrected refraction and spherical additions between -5.0 D to +1.5 D in 0.5 D steps. Defocus curve will be performed monocularly. The patient will be presented with the spherical additions in the order from -5.0 D to +1.5 D.
Measured: 1month and 3 months after treatment
Contrast sensitivity
Contrast sensitivity testing will be performed monocularly with the distance-corrected study eye under photopic with glare, mesopic and mesopic with glare conditions using CSV 1000. The testing will be performed at spatial frequencies of 3, 6, and 12 and 18 cycles/degree.
Mesopic contrast sensitivity testing (3 cd/m2) using mesopic filter installed in the patient trial frame, will be performed prior to the photopic testing (85 cd/m2). A minimum of 5 minutes should be provided for the patient's eye dark adaptation before the beginning of the mesopic contrast testing in a room with photopic light conditions.
The ambient illumination should be lower or at most equal to the chart luminance. The mesopic testing without glare will be performed first before testing with glare source provided with the testing device
Measured: 3 months after treatment
Subjective refraction
The assessment of refraction, which includes sphere (D), cylinder (D), and axis (°), will be conducted through subjective and objective methods. Objective refraction will follow standard clinical practice and will be performed by the Investigator or trained staff. Subjective testing will be conducted using trial frames instead of a phoropter. Consistency in the refractive technique should be maintained throughout the entire study duration. Test optotypes such as Sloan letters (e.g., ETDRS charts) will be used.
The cylinder value should be recorded in negative notation. Cylinder refraction should be performed for every patient. If the cylinder refraction is zero, the cylinder axis should be marked as not applicable. A pre-sign for the sphere is only necessary for negative values. If no pre-sign is entered, it indicates a positive value
Measured: 1 week, 1month and 3 months after treatment
Near addition
Monocular CNVA with near addition. Designed to create additional foci in the implanted IOL which will give near vision without loss of far vision.
Measured: 1 week, 1 month and 3 months after treatment
Slit Lamp examination findings
Slit lamp examination will be performed using a slit lamp biomicroscope. The subject will be seated. During this examination the eyes might be dilated depending on doctors' decision. The following will be examined during the examination conjunctiva, cornea, anterior chamber, iris, eyelid. Magnification will be consistent with standard clinical practise.
The observation will be graded as normal or abnormal. In case of abnormal observations subjective graded according to the grading scales will be used. The abnormal grading will then be graded as clinical significant or not clinically significant. In case of clinically significant observation the event will be specified and will be collected as adverse events.
Measured: 1 week, 1month and 3 months after treatment
Fundus examination findings
To examine the retinal integrity and document the safety of the procedure a full fundus examination will be performed using a slit lamp and dilated pupil for a clear view.
Measured: 1 week, 1month and 3 months after treatment
Intraocular pressure
The intraocular pressure (IOP) will be measured using air tonometry
Measured: 1 week, 1month and 3 months after treatment
Spectacle independence questionnaire
The questionnaire in the Czech language will be explained to the patient and handed over by the staff. It consists of 9 questions with multiple-choice answers as standard.
The questions request answers on the following scale: All the time / Most of the time / Sometimes / Rarely / Never.
The best response is never.
Measured: 3 months after treatment
QoV patient questionnaire
The questionnaire in the Czech language will be explained to the patient and handed over by the staff. It consists of 10 questions as standard. All of the questions have 4 possible answers: Never / Occasionally / Often / Frequently. The worst outcome is frequently.
Measured: 3 months after treatment
Adverse Events
During the course of the planned clinical investigation, utmost attention will be given to detecting any potential adverse events or unfavourable discoveries.All findings related to adverse events must be documented in the "Adverse Event (AE)" section of the subject's worksheets (CRFs). These events are categorized as either serious or non-serious, as well as related or unrelated to the investigational device/procedure. The method of reporting or documenting these adverse events varies depending on their category (serious or non-serious).
Measured: 1 week, 1month and 3 months after treatment
Device deficiency
An inadequacy of a medical device with respect to its identity, quality, durability, reliability, safety usability, safety or performance. Device deficiencies include includes malfunctions, use errors, and inadequacy in the information supplied by the manufacturer including labelling. This definition includes device deficiencies related to the investigational medical device. DD can become (might lead to) serious adverse events (SAE) if:
- suitable action had not been taken, or
- intervention had not been made, or
- if circumstances had been less fortunate These DDs are handled using the SAE reporting system.
Measured: 1 week, 1 month and 3 months after treatment
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted3 Feb 2026
- Study start15 Oct 2023
- Primary completion12 Nov 2024
- Study completion12 Nov 2024
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for PresbyopiaStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 19 participants (actual)
Sponsor and investigators
- Lead sponsor
- Perfect Lens, LLC
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
- Investigators
- Pavel Stodulka, PhD FEBOS-CR, Principal investigator, Gemini Eye Center
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07384182
- Sponsor's protocol ID
- PL-RISO1
- Status last verified
- Feb 2026
- First submitted
- 19 Jan 2026
- Last updated
- 5 Feb 2026
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Yes: All of the individual participant data collected during the trial, after deidentification, will be shared.
Study at a glance
From the registry record, last updated by the sponsor on 5 Feb 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Assessment of Clinical and Refractive Outcomes of the Use of a Femtosecond to Treat the Symptoms of Presbyopia in a Patient With Implanted Mono Focal IOLs
- ClinicalTrials.gov ID
- NCT07384182
- Acronym / sponsor ID
- PL-RISO1
- Conditions
- Presbyopia
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 19 participants (actual)
- Lead sponsor
- Perfect Lens, LLCIndustry (pharma, biotech, devices)
- Study start
- 15 Oct 2023 (actual)
- Primary completion
- 12 Nov 2024 (actual)
- Study completion
- 12 Nov 2024 (actual)
- First posted
- 3 Feb 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study aimed to assess the safety and efficacy of treating presbyopia in eyes implanted with a mono focal IOL using a low-energy femtosecond laser.
Detailed description
An investigative device built by Perfect Lens was used to adjust an implanted IOL in 38 eyes.
The device uses a femtosecond laser, a scanner, and an OCT. Each patient was presbyopic pre-treatment. The primary endpoint for the treatment was to create near vision in the treated eye without sacrificing the existing far vision. The first patient was treated in October 2023 and the last patient was treated in July 2024. The last patient visit was in November 2024.
The patients were examined at 7 days, 30 days and 90 days after treatment.
Study design
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Application of Perfector laser treatment | Experimental | Device: PerfectorActive treatment arm |
Who may qualify
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Child, Adult, Older adult
Key inclusion criteria (4 listed)
- Ability to understand study requirements, follow study instructions and to return for required study follow-up visits as confirmed by provision of written informed consent;
- Subject has undergone cataract surgery and has had a monofocal lens implanted in both eyes;
- Subject has no significant residual visual issues which the Investigator believes would make the patient ill suited for the Treatment.; and
- Both eyes have CDVA vision of 20/25 or better at 4m.
Key exclusion criteria (13 listed)
- Subjects not able to complete the informed consent form;
- Clinically significant corneal abnormalities including corneal dystrophy (e.g., epithelial, stromal, or endothelial dystrophy), inflammation, keratitis, keratoconjunctivitis, keratouveitis, keratopathy, keratectasia or edema per the Investigator's expert medical opinion;
- Previous corneal surgery;
- Previous refractive surgery or proposed refractive surgery procedures throughout the entire duration of the subjects' participation in the clinical study (including, but not limited to LASIK, astigmatic keratotomy and limbal relaxing incisions);
- History of or current retinal conditions or predisposition to retinal conditions including retinal detachment, diabetic retinopathy, age related macular degeneration which are assessed to by investigator to confound outcomes;
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| PerfectorThe Perfector is used in the procedure. The Device is attached to the patient by the use of a patient attachment. The patient attachment attaches to the sclera of the eye using vacuum pressure. | Device | Application of Perfector laser treatment |
Primary outcome
Distance corrected near visual acuity (DCNVA) at 40 cm
Time frame: 1 month after treatment
Visual acuity (VA) was tested monocularly and binocularly (both eyes together) using the manifest refraction and the hand-held, 100% contrast, Early Treatment Diabetic Retinopathy Study (ETDRS) chart set at 40 centimeters (cm) on the nearpoint rod. VA was measured in logarithm minimum angle of resolution (logMAR) increments, with 0.1 logMAR corresponding to 5 letters, or 1 line, on the ETDRS chart. A lower logMAR value denotes better visual acuity. The hypothesis tested for is to demonstrate superiority of the near vision of treated IOL to the IOL pre-treatment.
Distance corrected intermediate visual acuity (DCIVA) at 66 cm
Time frame: 1 month after treatment
Visual acuity (VA) was tested monocularly and binocularly (both eyes together) using the manifest refraction and the hand-held, 100% contrast, Early Treatment Diabetic Retinopathy Study (ETDRS) chart set at 66 centimeters (cm) on the nearpoint rod. VA was measured in logarithm minimum angle of resolution (logMAR) increments, with 0.1 logMAR corresponding to 5 letters, or 1 line, on the ETDRS chart. A lower logMAR value denotes better visual acuity. The hypothesis tested for is to demonstrate non-inferiority of the treated IOL to the pre-treated IOL (using a non-inferiority margin of 0.10 logMAR).
Corrected distance visual acuity (CDVA) at 4 m
Time frame: 1 month after treatment
Visual acuity (VA) was tested monocularly and binocularly (both eyes together) using the manifest refraction adjusted for infinity and stand Early Treatment Diabetic Retinopathy Study (ETDRS) chart set at 4 meters (m) on the nearpoint rod. VA was measured in logarithm minimum angle of resolution (logMAR) increments, with 0.1 logMAR corresponding to 5 letters, or 1 line, on the ETDRS chart. A lower logMAR value denotes better visual acuity. The hypothesis tested for the co-primary effectiveness endpoint is to demonstrate non-inferiority of the treated IOL to the pre-treatment IOL (using a non-inferiority margin of 0.10 logMAR).
15 secondary outcomes
Uncorrected distance visual acuity (UDVA)
Time frame: 1 week, 1month and 3 months after treatment
Uncorrected intermediate visual acuity at 66 cm (UIVA)
Time frame: 1 week, 1month and 3 months after treatment
Uncorrected near visual acuity at 40 cm (UNVA)
Time frame: 1 week, 1month and 3 months after treatment
Corrected near visual acuity at 40 cm (CNVA)
Time frame: 1 week, 1month and 3 months after treatment
Defocus curve
Time frame: 1month and 3 months after treatment
Contrast sensitivity
Time frame: 3 months after treatment
Subjective refraction
Time frame: 1 week, 1month and 3 months after treatment
Near addition
Time frame: 1 week, 1 month and 3 months after treatment
Slit Lamp examination findings
Time frame: 1 week, 1month and 3 months after treatment
Fundus examination findings
Time frame: 1 week, 1month and 3 months after treatment
Intraocular pressure
Time frame: 1 week, 1month and 3 months after treatment
Spectacle independence questionnaire
Time frame: 3 months after treatment
QoV patient questionnaire
Time frame: 3 months after treatment
Adverse Events
Time frame: 1 week, 1month and 3 months after treatment
Device deficiency
Time frame: 1 week, 1 month and 3 months after treatment
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 5 Feb 2026.
- Individual participant dataSharing planned: Yes. All of the individual participant data collected during the trial, after deidentification, will be shared.
Related trials for Presbyopia
Recruiting
Evaluation of Functional Superiority of the Morrow eProgressive
Presbyopia
Active, not recruiting
Clinical Trial With Artiflex Presbyopic (Artiplus)
Presbyopia, Ametropia
Recruiting
VisDura VisAbility™ Micro Insert System Pre-market Clinical Trial
Presbyopia
Recruiting
Volumetric Visual Fields at Intermediate and Near Distances in Presbyopic Patients Using Occupational and General-Purpose Progressive Addition Lenses
Presbyopia
Recruiting
Volumetric Visual Fields at Different Distances in Presbyopic Patients Using Occupational (PC-133 and PC-200) and General-Purpose Progressive Addition Lenses
Presbyopia
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Pavel Stodulka, PhD FEBOS-CR principal investigator
Gemini Eye Center
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Perfector in people with Presbyopia, run by Perfect Lens, LLC at 1 site in Czechia.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 13 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 5 Feb 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Czechia. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Distance corrected near visual acuity (DCNVA) at 40 cm (time frame: 1 month after treatment). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 5 Feb 2026.